Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF

Aymara Fernández Lorente1, Soraida Acosta Brooks, Elia Neninger Vinageras

  • 1Center of Molecular Immunology, Clinical Research Direction, PO Box: 16040, Havana 11600, Cuba. aymaraf@cim.sld.cu.

Abstract

Insights

CIMAvax® EGF cancer vaccine did not negatively impact wound healing in surgical patients. This study found no adverse events related to wound healing in patients treated with the epidermal growth factor (EGF) vaccine.

Area of Science:

  • Oncology
  • Immunology
  • Wound Healing Research

Background:

  • The epidermal growth factor receptor (EGFR) signaling pathway is dysregulated in many cancers, making it a therapeutic target.
  • EGFR also plays a critical role in cutaneous wound healing processes.
  • CIMAvax® EGF is a cancer vaccine designed to block EGF-EGFR interaction, demonstrating safety and efficacy in non-small cell lung cancer patients.

Observation:

  • A retrospective study reviewed medical records of 452 patients vaccinated with CIMAvax® EGF.
  • Six patients who underwent surgical treatment while on CIMAvax® EGF therapy were identified for detailed analysis.
  • Wound healing complications were assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTC) version 3.0.

Findings:

  • None of the six surgical patients treated with CIMAvax® EGF experienced wound healing complications.
  • Specifically, no instances of wound dehiscence, infection, delayed healing, fistula, abscess, or significant bleeding were observed.

Implications:

  • The findings suggest that CIMAvax® EGF vaccination does not adversely affect surgical wound healing.
  • This indicates a potential for concurrent use of CIMAvax® EGF with surgical interventions without compromising patient recovery.
  • Further research could explore the specific mechanisms underlying the lack of negative impact on wound repair.

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...
31